乌帕替尼对实验性自身免疫性葡萄膜炎的治疗效果:单细胞分析的启示
本研究利用单细胞RNA测序和单细胞ATAC测序分析Vogt-Koyanagi-Harada(VKH)病患者外周血单个核细胞及实验性自身免疫性葡萄膜炎(EAU)小鼠颈引流淋巴结细胞的JAK/STAT通路。乌帕替尼治疗可有效缓解EAU症状、降低JAK1蛋白表达、抑制致病性CD4 T细胞增殖与致病性并促进Treg增殖,同时抑制CXCR4介导的细胞迁移通路。
要点
- VKH病患者和EAU中JAK/STAT通路均上调。
- 乌帕替尼缓解EAU症状并降低JAK1蛋白表达。
- 乌帕替尼抑制致病性CD4 T细胞并促进Treg增殖。
核心结论
- JAK1介导的信号通路在葡萄膜炎中显著上调,乌帕替尼对EAU表现出治疗功效。
- 靶向CXCR4介导的迁移通路可能是一种有前景的治疗策略。
研究设计与样本
- 利用单细胞RNA测序和单细胞ATAC测序分析12例VKH病患者外周血单个核细胞及EAU颈引流淋巴结细胞的JAK/STAT通路。
- 用乌帕替尼治疗EAU后,整合单细胞RNA数据分析免疫细胞基因表达和细胞间通讯。
- 应用流式细胞术和蛋白质印迹分析颈引流淋巴结细胞。
主要发现
- JAK/STAT通路在VKH病患者和EAU中上调。
- 乌帕替尼有效缓解EAU症状、降低JAK1蛋白表达、抑制致病性CD4 T细胞增殖与致病性并促进Treg增殖。
- 流式细胞术和单细胞RNA数据均观察到乌帕替尼对致病性CD4 T细胞的抑制。
- 乌帕替尼可挽救ISG15+ CD4 T细胞及CD8 T与B细胞比例,并减少炎症相关基因表达。
- 乌帕替尼能抑制异常激活的细胞间通讯,尤其是与EAU发病相关的CXCR4介导的迁移通路;CXCR4抑制剂在EAU中显示出有前景的治疗效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to elucidate the impact of upadacitinib, a Janus kinase 1 (JAK1)-specific inhibitor, on experimental autoimmune uveitis (EAU) and explore its underlying mechanisms. METHODS: We utilized single-cell RNA sequencing (scRNA-seq) and single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq) to investigate the JAK/signal transducer and activator of transcription (STAT) pathway in peripheral blood mononuclear cells (PBMCs) of 12 patients with Vogt-Koyanagi-Harada (VKH) disease and cervical draining lymph node (CDLN) cells of EAU. After treating EAU with upadacitinib, we analyzed immune cell gene expression and cell-cell communication by integrating scRNA data. Additionally, we applied flow cytometry and western blot to analyze the CDLN cells. RESULTS: The JAK/STAT pathway was found to be upregulated in patients with VKH disease and EAU. Upadacitinib effectively alleviated EAU symptoms, reduced JAK1 protein expression, and suppressed pathogenic CD4 T cell (CD4TC) proliferation and pathogenicity while promoting Treg proliferation. The inhibition of pathogenic CD4TCs by upadacitinib was observed in both flow cytometry and scRNA data. Additionally, upadacitinib was found to rescue the interferon-stimulated gene 15 (ISG15)+ CD4TCs and CD8 T and B cell ratios and reduce expression of inflammatory-related genes. Upadacitinib demonstrated the ability to inhibit abnormally activated cell-cell communication, particularly the CXCR4-mediated migration pathway, which has been implicated in EAU pathogenesis. CXCR4 inhibitors showed promising therapeutic effects in EAU. CONCLUSIONS: Our findings indicate that the JAK1-mediated signaling pathway is significantly upregulated in uveitis, and upadacitinib exhibits therapeutic efficacy against EAU. Furthermore, targeting the CXCR4-mediated migration pathway could be a promising therapeutic strategy.
引用
- Huang Z, Jiang Q, Chen J, et al. Therapeutic Effects of Upadacitinib on Experimental Autoimmune Uveitis: Insights From Single-Cell Analysis. Invest Ophthalmol Vis Sci. 2023. PMID: 37713206. doi:10.1167/iovs.64.12.28
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。